Katy Beckermann, MD, PhD

Kathryn Beckermann, MD, PhD, is an Assistant Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, at Vanderbilt University Medical Center. She is a GU medical oncologist specialized in treating kidney, bladder, prostate, and testicular cancer.

Articles by Katy Beckermann, MD, PhD

Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
View More
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | June 17, 2024
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann review JAVELIN Renal 101, focusing on the impact of avelumab and axitinib treatment on RCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann discuss the evolving significance of sarcomatoid histology in guiding treatment decisions for RCC.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | April 11, 2024
Drs. Atkins and Beckermann weigh the potential of targeting Tregs in RCC treatment, particularly in relation to PD-1 therapy.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | April 11, 2024
Drs. Atkins and Beckermann consider biomarkers for patient selection for LAG-3 inhibition and increasing cure rates in RCC.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | April 11, 2024
Drs. Atkins and Beckermann discuss LAG-3 as a novel checkpoint inhibitor combined with anti-PD-1 for kidney cancer.cC
Katy Beckermann, MD, PhDRenal Cell Carcinoma | March 6, 2024
Drs. Beckermann and Hutson compare the QOL data for tivozanib and belzutifan in patients with relapsed or refractory aRCC.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | March 6, 2024
Drs. Hutson and Beckermann summarize the long-term TIVO-3 data for patients with relapsed or refractory advanced RCC.
Rana McKay, MDRenal Cell Carcinoma | May 31, 2024
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
Rana McKay, MDRenal Cell Carcinoma | May 31, 2024
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
Rana McKay, MDRenal Cell Carcinoma | May 31, 2024
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
Rana McKay, MDRenal Cell Carcinoma | May 31, 2024
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
Rana McKay, MDRenal Cell Carcinoma | May 31, 2024
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
Rana McKay, MDRenal Cell Carcinoma | May 31, 2024
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.